News

2021.07.16

CLS001 Clinical Study Plan Officially Approved by MHLW‘s Health Science Council

Tokyo (July 16, 2021)-, Japanese Ministry of Health and Labor, and Welfare approved the first in human clinical research plan to transplant corneal endothelial cell substitute from iPS cells into Bullous Keratopathy patients on July 14th. The plan has been approved from Japanese MHLW’s Health Science Council held on June 30th under the conditions of minor document collections by now. The research will be leaded by Prof. Shigeto Shimmura’s team, the collaborator of Cellusion, in Keio University. The study will start in Keio University hospital once all preparations are finished.

Parallel to this clinical study, Cellusion is preparing for starting P1/2 clinical trial in Japan. With our cutting-edge cellular technology, Cellusion will accelerate our research program to deliver novel therapies for all bullous keratopathy patients.

<About Cellusion Inc.>
Cellusion Inc. is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.
Company : Cellusion Inc.
CEO : Shin Hatou, M.D., Ph.D.
Headquarter :1-13-7 Nihombashi-Muromachi, Chuo, Tokyo 103-0022, JAPAN
Founded : January 2015
URL : https://cellusion.jp/en/

COPYRIGHT CELLUSION ALL RIGHTS RESERVED.